Migraine is a highly disabling neurological condition, and preventative 
treatment still remains problematic, due to aspecificity of the majority of the 
currently available prophylactic drugs. Calcitonin-gene-related peptide (CGRP) 
plays a crucial role in migraine pathophysiology; agents aimed at blocking its 
activity have, therefore, been developed in recent years, among which are 
monoclonal antibodies (mAbs) against CGRP, to prevent migraine. Erenumab is the 
only mAb that targets the CGRP receptor instead of the ligand, with high 
specificity and affinity of binding. This review will report on the most recent 
data on erenumab characteristics and on the results of clinical trials on its 
employment in the prevention of episodic migraine (4-14 monthly migraine days): 
one Phase II and two Phase III trials (completed) and one Phase III trial 
(ongoing). Monthly subcutaneous administration (70 mg or 140 mg) of erenumab vs 
placebo for 3-6 months showed significantly higher efficacy in reducing the mean 
monthly number of migraine days and the use of migraine-specific medication, and 
in decreasing physical impairment and impact of migraine on everyday activities 
(P<0.001). A favorable safety profile was demonstrated by the lack of 
significant differences in the occurrence of adverse events in erenumab-treated 
vs placebo-treated patients. Global results so far obtained point to erenumab as 
a new promising candidate for the preventative treatment of episodic migraine. 
Licence applications for erenumab were recently submitted to the Food and Drug 
Administration in the USA and European Medicines Agency in Europe (May/June 
2017).